Silkim Pharma Company
"Novel Drugs Targeting Inflammatory Pathologies."
Silkim Pharma developed a novel, protected platform of drugs for proven treatments of multiple indications.
The platform is the result of extensive investigation of animal models of human diseases. Members of the platform act as potent anti-inflammatory agents, strong iron chelating agents, and anti-biotic agents. These Modes of Action jointly assist in treating the causes and/or symptoms of multiple indications.
Silkim Pharma recently developed Coronzot, a novel family of medications against COVID-19, which employs a novel mechanism based on sequestration of the labile iron, introducing an ion of gallium or zinc, in limited amounts, instead. The drug aims to solve the phenomenon called Cytokine Release Syndrome (CRS) which is the exaggerated reaction of the body’s immune system, triggered by the virus, producing overaccumulation of labile, redox-active iron.
Combating Coronavirus Pandemic:
Silkim Pharma's solution helps address the Coronavirus Pandemic.
Silkim Pharma developed a novel, protected platform of drugs for proven treatments of multiple indications.
The platform is the result of extensive investigation of animal models of human diseases. Members of the platform act as potent anti-inflammatory agents, strong iron chelating agents, and anti-biotic agents. These Modes of Action jointly assist in treating the causes and/or symptoms of multiple indications.
Silkim Pharma recently developed Coronzot, a novel family of medications against COVID-19, which employs a novel mechanism based on sequestration of the labile iron, introducing an ion of gallium or zinc, in limited amounts, instead. The drug aims to solve the phenomenon called Cytokine Release Syndrome (CRS) which is the exaggerated reaction of the body’s immune system, triggered by the virus, producing overaccumulation of labile, redox-active iron.
Combating Coronavirus Pandemic:
Silkim Pharma's solution helps address the Coronavirus Pandemic.
Technology:
COVID Treatments
Industry:
Vaccine Development
Headquarters:
Israel
Founded Date:
2013
Employees Number:
N/A
Funding Status:
N/A
Register and Claim Ownership